Welcome to LookChem.com Sign In|Join Free
  • or


Post Buying Request

125317-39-7 Suppliers

Recommended suppliersmore

Product FOB Price Min.Order Supply Ability Supplier
High Purity Vinorelbine Ditartrate
Cas No: 125317-39-7
USD $ 50.0-100.0 / Gram 1 Gram 5 Kilogram/Month Beijing Yibai Biotechnology Co., Ltd Contact Supplier
Vinorelbine tartrate
Cas No: 125317-39-7
No Data No Data No Data Jinan Baozhao Pharmaceutical Co., Ltd Contact Supplier
Vinorelbine tartrate Manufacturer/High quality/Best price/In stock
Cas No: 125317-39-7
USD $ 3.0-3.0 / Kilogram 1 Kilogram 1-100 Metric Ton/Month Hangzhou Dayangchem Co., Ltd. Contact Supplier
Vinorelbine tartrate 125317-39-7 in Bulk Supply
Cas No: 125317-39-7
USD $ 800.0-1000.0 / Kilogram 1 Kilogram 4000 Kilogram/Month Kono Chem Co.,Ltd Contact Supplier
Vinorelbine Ditartrate
Cas No: 125317-39-7
No Data 10 Milligram Amadis Chemical Co., Ltd. Contact Supplier
Vinorelbine bitartrate
Cas No: 125317-39-7
No Data No Data No Data Chemwill Asia Co., Ltd. Contact Supplier
Vinorelbine 125317-39-7
Cas No: 125317-39-7
USD $ 1.0-1.0 / Kilogram 1 Kilogram 200 Metric Ton/Day Henan Sinotech Import&Export Corporation Contact Supplier
125317-39-7 C53H66N4O20 Vinorelbine tartrate
Cas No: 125317-39-7
USD $ 1.0-1.0 / Kilogram 1 Kilogram 100 Kilogram/Month HENAN SUNLAKE ENTERPRISE CORPORATION Contact Supplier
Factory Vinorelbine Ditartrate 99% in stock CAS NO.125317-39-7
Cas No: 125317-39-7
No Data 1 Gram 1 Metric Ton/Month Shaanxi Mingqi Chemical Co., Ltd Contact Supplier
Vinorelbine tartrate factory price 99%50KG in stock
Cas No: 125317-39-7
USD $ 1.0-1.0 / Kilogram 1 Kilogram 100 Kilogram/Month Shenzhen Tianyuan Pharmaceutical Technology Co., Ltd Contact Supplier

125317-39-7 Usage

Pharmacological effects

Vinorelbine tartrate is the tartrate form of vinorelbine ,it is a semi-synthetic  vincristine compound, it belongs to M phase specific drugs, mechanism of action is similar to vincristine . Mainly it , by selectively blocking mitotic cell tubulin polymerization to form microtubule and  inducing tubulin depolymerization , impedes spindle microtubules,and it makes cell division stop  in the middle, and it has few effect on the synthetic tubulin in the shaft of nerve cells. Since NVB affinity for axonal microtubules is poor, only when there is a high concentration of it ,it has effect on axonal , so it has the lower neurotoxicity than other vincristine drugs,and it  has a greater therapeutic index. Human pharmacokinetics of vinorelbine show that after intravenous administration there is a three-compartment model, the volume  of distribution is large , PPB is up to 50% to 80%, plasma clearance rate is high, the terminal elimination phase T1/2 is 40 h, it has a rapid tissue distribution, concentration in tissues is significantly higher than vincristine (VCR), vindesine (VDS). Plasma clearance is 0.8 L/(kg • h),it is mainly through biliary secretion, and it is excreted with the feces, urine excretion accounts for 10% to 15%.It has a higher efficacy and less adverse reactions of the nervous system.


An antineoplastic

Adverse reactions

  • Vinorelbine hematologic toxicity is dose-limiting , mainly it is neutropenia, which mostly restore  within 7d, it has a certain influence on red blood cells , thrombocytopenia and anemia incidence is less than 2%.
  • Neurotoxicity mainly performs as tendon reflexes (about 25%), occasional paresthesia, few patients may have gastrointestinal autonomic nerve paralysis induced constipation (17%~41%),  paralytic ileus is rare  , 2% 6% of the patients suffer finger (toe) numb, but the incidence is much lower than the VCR and VDS.
  • Incidence of gastrointestinal side effects is less than 10%. Occasionally, nausea, vomiting, dyspnea, and bronchospasm, often occur in a few minutes or several hours after treatment . Alopecia incidence is less than 10%.
  • Vinorelbine drug extravasation into the surrounding tissue can cause burning, injection site phlebitis, local tissue necrosis, ulceration, cellulitis.
  • Myelosuppression is dose-limiting toxicity. 3 to 5 days after the medication, transient myelosuppression can occur, usually it can recover within 10 days, attention should be paid to prevent infection. Neurotoxicity is visible.

Brand name

Navelbine (Pierre).


Antineoplastic agents

Clinical evaluation

Numerous clinical studies have shown that vinorelbine is one of the most effective drugs for the treatment of non-small cell lung cancer and breast cancer, single agent response rate is 14% to 35% and 30% to 60% respectively. And DDP combination chemotherapy in NSCLC and with doxorubicin combination therapy of breast cancer, efficiency is up to 30% to 50% and 50% to 77%, respectively. It has a good effect on ovarian cancer, malignant lymphoma, head and neck cancer, esophageal cancer.


Vinorelbine belongs to vinblastine derivatives, its action is similar to vincristine. It is first marketed in 1989 in France. The main role is to combine tubulin, consequently, it causes microtubule formation disorder during cells mitosis.
Vinorelbine belongs to cycle specific drugs, it is used clinically in the treatment of non-small cell lung cancer (NSCLC) and breast cancer, ovarian cancer, head and neck squamous cell carcinoma, leukemia. In addition,it also has a strong inhibitory effect on small cell lung cancer, colon cancer, brain tumors, malignant melanoma.


ChEBI: The L-(+)-tartrate salt of vinorelbine.

Chemical properties

White or almost white powder or crystalline powder, odorless.

Chemical Properties

Pale Yellow Powder

Biological Activity

Selective mitotic microtubule antagonist that exhibits > 20 fold selectivity over axonal microtubules. Inhibits proliferation of multiple human tumor cell lines (IC 50 = 1.25 nM in HeLa cells) and blocks metaphase/anaphase transition by suppression of microtubule dynamics (IC 50 = 3.8 nM). Reduces spindle length by 29% and inhibits microtubule polymerization at micromolar concentrations.

125317-39-7 Well-known Company Product Price

Brand (Code)Product description CAS number Packaging Price Detail
USP (1714506)  Vinorelbine tartrate  United States Pharmacopeia (USP) Reference Standard 125317-39-7 1714506-200MG 44,939.70CNY Detail
Sigma-Aldrich (Y0000463)  Vinorelbine tartrate  European Pharmacopoeia (EP) Reference Standard 125317-39-7 Y0000463 1,880.19CNY Detail



According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017


1.1 GHS Product identifier

Product name vinorelbine L-tartrate

1.2 Other means of identification

Product number -
Other names Vinorelbine tartrate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:125317-39-7 SDS

125317-39-7Downstream Products

Please post your buying leads,so that our qualified suppliers will soon contact you!

*Required Fields